<?xml version="1.0" encoding="UTF-8"?>
<p>Monoclonal antibodies are synthesized by one unique parental cell and thus bind to a unique epitope. To date, several mAbs have been approved by the FDA for viral infections including SARS-CoV-2 [
 <xref rid="B199-ijms-21-05559" ref-type="bibr">199</xref>]. IL-6 is an attractive target for mAb therapy due to its role in cytokine storm mediated lung inflammation [
 <xref rid="B200-ijms-21-05559" ref-type="bibr">200</xref>], body temperature regulation and fever. In a study on 20 patients with COVID-19 in Anhui, China more than 75% of patients admitted to ICU who were given tocilizumab showed improvement in oxygen saturation and 90% reported resolution of lung opacities on CT scans, while CRP decreased in 84% [
 <xref rid="B80-ijms-21-05559" ref-type="bibr">80</xref>]. In order to compare the efficiency of tocilizumab and favipiravir, a randomized controlled trial has been registered in China (ChiCTR2000030894) [
 <xref rid="B201-ijms-21-05559" ref-type="bibr">201</xref>]. Sarilumab (Kevzara) is another IL-6 receptor antagonist (recombinant humanized anti IL-6R monoclonal antibody) approved for treatment of rheumatoid arthritis [
 <xref rid="B202-ijms-21-05559" ref-type="bibr">202</xref>]. It is currently being evaluated in a Phase 2/3 clinical trial enrolling hospitalized adult COVID-19 patients, sponsored by Sanofi and Regeneron Pharmaceuticals (NCT04315298).
</p>
